Principal Financial Group
EVFM

Principal Financial Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Principal Financial Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,101
Closed -$12K – 2686
2021
Q3 		$12K Sell
1,101
-178
-14% -$2.24K ﹤0.01% 2574
2021
Q2 		$22K Sell
1,279
-984
-43% -$18.7K ﹤0.01% 2596
2021
Q1 		$60K Sell
2,263
-84
-4% -$3.82K ﹤0.01% 2449
2020
Q4 		$84K Buy
2,347
+1,637
+231% +$59.2K ﹤0.01% 2371
2020
Q3 		$25K Buy
+710
New +$30.9K ﹤0.01% 2311

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Principal Financial Group's EVFM Position: Q4 2021 in Review

Principal Financial Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 1,101 shares — an estimated $12K sold.

Principal Financial Group first reported a position in EVFM in Q3 2020 and held it in 5 quarters. The position peaked at $84K in Q4 2020. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

  • Principal Financial Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 1,101 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $12K.
  • Principal Financial Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Principal Financial Group's Evofem Biosciences, Inc. Common Stock position peaked at $84K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.